Novo Nordisk A/S (NVO) — closed signal from October 29, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 27, 2026.
Predicted vs. what happened
What happened
Reached its target in 85 days.
The thesis — published October 29, 2025
Novo Nordisk's share price has cooled off after a sharp drop, just as a big FDA decision on the pill version of Wegovy approaches. Job cuts tied to a reorg may cause headlines, but the core business is still strong. Over the next 0-3 months, a positive ruling could lift mood and price. Buying near $52 aims for a fair entry while staying mindful that any delay in the decision could push the timeline out.
Primary drivers
- Key FDA call on oral Wegovy that could expand the obesity treatment market
- Price pulled back hard, so even modest good news may spark a stronger rebound
- Healthy profits and cash flow support ongoing research, launches, and scaling
- Restructuring headlines may distract investors and add short-term ups and downs
How it played out
NVO: target reached in 85 days
Lyra published NVO at $52.45 on 2025-10-29, with 19% expected growth over a short-term window. The thesis pointed to a key FDA call on oral Wegovy, a hard price pullback, healthy profits and cash flow, and restructuring headlines that could add short-term ups and downs.
Inside the window, the stock reached the $62.42 target in 85 days. It peaked at $64.16 on 2026-01-23, a 22.3% gain. It ended the window at $62.89 on 2026-01-27. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.